A carregar...
Laboratory monitoring of hemophilia A treatments: new challenges
Monitoring factor VIII (FVIII) activity has traditionally been complicated by discrepancies between assays for the various sorts of FVIII molecules. The advent of novel nonfactor therapies (emicizumab, fitusiran, and anti-tissue factor pathway inhibitor antibodies) in hemophilia A poses a new level...
Na minha lista:
| Publicado no: | Blood Adv |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7218434/ https://ncbi.nlm.nih.gov/pubmed/32396619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000849 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|